In contrast, women with cancer recurrence were positive for other molecular subtypes, including luminal-B HER2-negative, luminal-B HER2-positive, and non-luminal HER2-positive or triple-negative subtypes (63% vs. 37%, respectively; p = 0.0455). This evidence concerns the gene ERBB2 and cancer.